Liver Failure and Kidney Damage Information and Help

FRIDAY, June 13 (HealthDayNews) -- A landmark study examining the risk factors for rapid loss of kidney function and the link between kidney and heart diseases is being conducted by a number of centers across the United States.

The goal of the Chronic Renal Insufficiency Cohort (CRIC) study is to identify ways to prevent or improve the treatment of both problems. It's the first large, prospective epidemiological study in the United States to look at the health of people with chronic kidney disease.

Researchers will try to determine why kidney disease gets worse faster in some people and why some are more prone to heart disease. Over two years, 3,000 volunteers will be recruited for the study, which is funded by the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

The CRIC study is recruiting people with varying degrees of kidney function, half of whom will have kidney disease due to diabetes.

Study volunteers will continue to receive regular health care from their own doctors. At the same time, CRIC researchers will monitor the health of each patient for up to six years. They'll perform standard blood, urine and other tests to measure kidney, heart and blood vessel health.

About one-third of the study volunteers will be given a glomerular filtration test, which measures kidney function more accurately than standard tests. Some patients will also have electron beam tomography. It's a fairly new test that measures calcium in the heart's arteries and may identify heart disease earlier than standard ECG and EKG tests.

The centers involved in the CRIC study are in Ann Arbor, Mich., Baltimore, Chicago, Cleveland, New Orleans, Oakland, Calif., San Francisco and Philadelphia.

Here's where you can get more information about the CRIC study.

In 2000, more than 458,000 people in the United States were treated for kidney failure. Another 10 million to 20 million people have earlier stages of kidney disease. All are at higher-than-average risk for heart attack, stroke and other health complications.

Serious Liver Injury:
Leading Reason for Drug Removals, Restrictions
By Michelle Meadows

People who experience acute liver failure become critically ill in a matter of days, with most cases resulting in the need for a liver transplant or even death. Drug-induced liver injury has become the number one cause of this rare syndrome. It's also the leading reason that drugs are removed from the market or require restricted use and special monitoring of patients.

During a drug's development, manufacturers conduct animal tests that include an assessment of potential toxic effects of the new drug on the liver. Additionally, liver function testing is conducted on humans to detect adverse reactions--some of which may keep the drug from making it to the market. But acute liver failure due to a new drug is a very rare event, and may show up only after a drug has been approved.

Because clinical trials typically involve several thousand subjects, they pick up common problems--affecting 1 person in 500 or 1 in 1,000, says Peter Honig, M.D., director of the Food and Drug Administration's office of postmarketing drug risk assessment. "But they aren't designed to pick up rare adverse events, occurring at a rate of 1 per 50,000 exposures," such as acute liver failure, he says. Liver injury can also be hard to predict because genetics may make one patient more susceptible to liver problems than others. Or, a drug may have toxic effects when used with other substances or when used too long.

Because liver failure also can occur rarely in people not exposed to drugs, it is often hard to know if early cases reported for a new drug were actually caused by the drug. When cases of liver injury are caused by a drug, whether before drug marketing or after, experts weigh the risk against the value of the drug. "Unless the drug is treating a life-threatening illness, a significant rate of severe injury (greater than 1 in 50,000 exposures) will lead to limiting the drug's use or withdrawing it from the market," Honig explains.

Most recently, the FDA asked Parke-Davis/Warner Lambert to voluntarily withdraw the diabetes drug Rezulin (troglitazone) from the market in March 2000. FDA officials had reviewed safety data showing that Rezulin is more toxic to the liver than two newer, similar drugs on the market, Avandia (rosiglitazone) and Actos (pioglitazone). And in 1998, the FDA asked Wyeth-Ayerst Laboratories to voluntarily remove the pain medication Duract (bromfenac) from the market. The FDA had received reports of liver failure associated with the drug when it was used for longer periods than the 10 days specified in the labeling.

Trovan (trovafloxacin/alatrofloxacin) is an example of a drug with significant limitations of use because of the potential for serious liver injury. The antimicrobial therapy treats a variety of infections, from mild to life threatening. Though no cases of liver failure, liver transplant, or death were reported in the 7,000 patients who took part in premarketing clinical trials for Trovan, the FDA began receiving reports of liver failure after Pfizer began marketing the drug in 1998. As a result, the FDA and Pfizer agreed to restrictions, which include limiting distribution of Trovan to inpatient facilities (hospitals, nursing homes) so doctors can closely monitor patients taking the drug. Trovan use was also limited to the treatment of patients with serious, life- or limb-threatening infections.

The FDA is working with other organizations to identify potential liver problems before drugs have been approved. And when that's not possible, experts want to spot problems quickly after marketing through spontaneous adverse event reporting. In February 2000, representatives from pharmaceutical companies, universities, and the FDA met in Chantilly, Va., to explore these goals.

Sponsored by the FDA, the American Association of the Study of Liver Diseases, and the Pharmaceutical Research and Manufacturers of America, the two-day workshop provided a forum to discuss pre-clinical, clinical, and postmarketing approaches related to drug-induced liver injury. These approaches include such areas as improving the quality of adverse event reports, conducting the best tests to detect liver abnormalities during a drug's development, and better interpreting laboratory findings.

One possible strategy for researchers, Honig says, will involve going back and evaluating animal test databases of those drugs known to cause severe liver damage in humans to see if certain laboratory test combinations are predictors of liver injury.

"We go over data rigorously and regularly examine possible signals that can predict liver injuries," Honig says. "But we need to learn more about the performance characteristics of the tests we are using." Performance characteristics refer to certain elements of liver function tests, alone or in combination, which can predict serious liver injury. Minor changes in one or more of the liver tests are very common in people in general, including patients enrolled in clinical trials.

"If you get too concerned about relatively small test elevations, you run the risk of stopping drug development or not approving drugs that are not toxic," Honig says. "At the same time, you don't want to ignore the subtle signals and approve drugs that are indeed toxic."

Visit the FDA's new Web page on drug-induced liver toxicity at www.fda.gov/cder/livertox.

--------------------------------------------------------------------------------

Medication Mistakes and Your Liver
Located behind the lower ribs on the right side of the abdomen, the liver is about the size of a football and the largest organ in the body. Because of its unique role in removing toxic substances from the blood, the liver is susceptible to damage from drugs. During chemical processes in the liver, toxic products are sometimes made that can damage the organ.

It is important to follow drug-prescribing requirements carefully and completely to avoid exceeding a drug's recommended dose or duration of use. Mixing certain medications together or with alcohol also can cause liver failure. Acetaminophen is a good example, says Eugene Schiff, M.D., president of the American Association for the Study of Liver Diseases and director of the Center for Liver Diseases at University of Miami's School of Medicine. "Millions of people take a drug like Tylenol safely," he says, "but for someone who is a regular alcohol user, it can wipe out the liver." McNeil Consumer Products, maker of Tylenol, warns that for this and other pain relievers, you should consult a doctor if you consume three or more drinks containing alcohol per day.

The FDA encourages consumers to learn the signs of liver disease, which can include abnormally yellow skin and eyes (jaundice), dark urine, light-colored stools, nausea, vomiting, and loss of appetite. Serious cases of liver injury may lead to sleep disturbances, mental confusion, and coma.

- -M.M.

--------------------------------------------------------------------------------

Drugs With Limitations
Due to potential liver problems, these are some drugs that have significant limitations on their use (warnings, dose restrictions, monitoring):
Niaspan Extended Release Tablets (niacin)
Dantrium (dantrolene)
Tylenol (acetaminophen)
Normodyne (labetalol)
Cylert (pemoline)
Felbatol (felbamate)
Zyflo (zileuton)
Tasmar (tolcapone)
Trovan (trovafloxacin, alatrofloxacin)

--M.M.

Kleinknecht D, Kanfer A, Morel-Maroger L, Mery JP.

(1) AIN is the most frequent pattern of drug-induced immunologically mediated renal injury. A number of drugs may be responsible for AIN, namely methicillin and other penicillin derivatives, rifampicin, phenindione and sulfonamides. Particular clinical and pathological features often suggest an immune pathogenetic mechanism. IgG anti-TBM and IgE antibodies have been found in only a few cases and it is likely that antibody-mediated and cell-mediated injury may operate in the same patient. (2) Only few examples of drug-induced vasculitis and glomerulonephritis are known, and the pathophysiology of this kind of renal damage is poorly understood.

ARAVA | AVANDIA | BAYCOL | BEXTRA |BENZINE | DISABILITY | ENBREL | EPHEDRA | FEN-PHEN LARIAM | LOTRONEX | MERIDIA | MEDICAL INSURANCE FRAUD | MEDICAL LAWSUITS | NORPLANT | NURSNG HOME NEGLIGENCE | OXYCONTIN | PPA | PERMAX | PREMPRO | PROPULSID | REMICADE | REZULIN LAWSUIT | RISPERDAL| SERZONE | SILICOSIS | STADOL | SULZER | STROKE| THIMEROSAL MERCURY AUTISM |VIOXX | WELDING FUMES PARKINSONS | WRONGFUL DEATH LAWSUIT | MESOTHELIOMA LAWSUIT | CLASS ACTION DEFINITION | LIPITOR | ZIAGEN | TOPAMAX | CYPHER CORONARY STENT | NORTREL | GENOTROPIN | VIGA |INTERGEL | VINEROL | LINDANE | PROCRIT | AVONEX | RAPAMUNE | SEREVENT | ANCURE ENDOGRAFT | VIOXX SIDE EFFECTS | ZYPREXA DIABETES?

Other Links and Sites :Class Action | Class Action Big | Class Action | AACSB | Financial Planner Certified | Ecommerce Solution

DMOZ Open Directory | About DMOZ

Attorney | Contact Us | Class Action Pros and Cons

All Rights Reserved 2002-2003 Mentz Law,LLC

LIVER AND KIDNEY DAMAGE REPORT

Liver and kidneys can be damaged by several drugs or medicines. If you are having kidney or liver failure, renal failure, high liver enzymes or diabetes, you may have taken a medication that has injured your body organs or caused the death of a loved one. Further , you may have been given professional medical help negligently.